Dr. Gregor Adams Joins MI Bioresearch as Director of Scientific Development

MI Bioresearch is pleased to announce that Dr. Gregor Adams has joined us as Director of Scientific Development. Dr. Adams received his Ph.D. from Imperial College School of Medicine in London, United Kingdom where his thesis focused on the development of a gene therapy for HIV-1 infection. He then continued his research career in cell […]

2018 MI Bioresearch Mid-Year Review

MI Bioresearch has started off 2018 with exciting advances in our available tumor models and capabilities to support your traditional oncology and immuno-oncology research. We have kept pace with the expanding scope of immuno-oncology research by deeper exploration of new models and novel methods to enhance our offerings to our […]

MI Bioresearch Updates Privacy Policy and Terms & Conditions

At MI Bioresearch we are committed to protecting your information. With that in mind, we have made some updates to our Privacy Policy and Terms & Conditions to make it easier for you to understand and be transparent about what information we collect, why we collect it, and how we use it. Our updated policy […]

Press Release: Xtalks to host MI Bioresearch’s Flow Cytometry Webinar

Flow Cytometry-Based Tools to Enrich Your Preclinical Immuno-Oncology Research, New Webinar Hosted by Xtalks Press Release – updated: Apr 30, 2018 08:00 EDT TORONTO, April 30, 2018 (Newswire.com) – In a live broadcast upcoming on Wednesday, May 16, 2018, at 1 p.m. EDT, industry experts from MI Bioresearch Dylan Daniel, Ph.D., director of scientific development, […]

2017 MI Bioresearch Year in Review

Immuno-Oncology Model Spotlights included: Murine Colon Cancer MC38 is one of the most commonly utilized syngeneic models to date. MI Bioresearch has been successfully able to acquire this line and we have generated an initial set of in vivo and flow cytometry data with it. MC38 Murine Ovarian Cancer ID8 […]

MI Bioresearch Teams Up With Champions Oncology

MI Bioresearch Extends its In Vivo Imaging and Targeted Radiation Capabilities to Champions Oncology PDX Models MI Bioresearch expands the possibilities for studying your oncology drug in clinically relevant PDX models from Champions Oncology. Champion’s offers over 900 well-characterized solid tumor PDX models across a wide range of indications. Do your PDX studies require in […]

Introducing MI GoFlow™ – Advancing Your Flow Cytometry

MI Bioresearch’s contract flow cytometry service, MI GoFlow™, provides you with an advanced flow cytometry resource to support your drug development needs. Run your sample generation studies with us or overnight-ship us your preclinical or non-CLIA regulated clinical samples and we’ll take care of the flow cytometry for you. MI GoFlow™ offers: Basic to comprehensive […]

MI Bioresearch Offers BLI Imaging in our ABSL2 Facility

We continue to build upon our heritage of being the first CRO to offer Bioluminescence Imaging (BLI) starting in 2003 and, to date, we have performed over 500 BLI studies. MI Bioresearch is now bringing its BLI expertise into its Animal Biological Safety Level 2 (ABSL2) facility. Since establishing an ABSL2 unit in 2016, MI […]

Preclinical Studies for CAR T-Cell Therapies

While CAR T-cell therapy has not been the overnight success that it first appeared to be, with the first CAR T-cells developed in the late 1980s, it remains a highly active area of preclinical and clinical development. The therapy involves extracting a patient’s own T-cells, expanding and genetically modifying them ex vivo to recognize a […]

Preclinical Studies for Your Oncolytic Virus Immunotherapy

Oncolytic virus immunotherapy is experiencing an increase in interest with several types of viruses having progressed to advanced efficacy trials. Recent FDA approval of a novel viral therapy demonstrates the potential of this therapeutic approach. The mechanism of action for virus therapy is based on the fact that certain viruses can enter cancer cells and replicate […]

Dylan Daniel, Ph.D. joins Molecular Imaging, Inc. as Director of Scientific Development

Dr. Daniel is an immunologist and preclinical oncology pharmacologist with leadership experience in all phases of early R&D for oncology and cancer immunotherapy. Dr. Daniel has a Ph.D. in Microbiology and Immunology and conducted post-doctoral work with Doug Hanahan at UCSF where he worked on immuno-oncology in genetically engineered mouse models. From there, Dr. Daniel […]

Molecular Imaging Launches New Name; Presents Posters at the American Association of Cancer Research Annual Meeting 2016

April, 2016 Ann Arbor, Mich., April 7, 2016 (BUSINESS WIRE) — Molecular Imaging, Inc. (MI), a leading preclinical oncology contract research organization, announces that, as of April 16, 2016, its name will change to “MI Bioresearch,” with the tagline “Advancing Your Preclinical Oncology.” The company will unveil its new branding at the American Association of Cancer Research […]

Standard Panels for Flow Cytometry Established

Download our Latest Panels (PDF) – October 2016   Standard Immunophenotyping Panels Accurate immunophenotyping by flow cytometry can uncover the mechanism of immuno-modulatory treatments.  Molecular Imaging offers a comprehensive line of antibody panels that enables identification and functional characterization of myeloid and lymphoid subsets that are key regulators of disease. Lymphoid Lineage Myeloid Lineage CD4+ […]

Molecular Imaging, Inc. has added the Attune™ NxT Flow Cytometer to its In Vitro Services

In Vitro Services at Molecular Imaging, Inc. takes Immuno-Oncology research to the next level by adding the Attune™ NxT Flow Cytometer to its instrumentation.  Fully upgraded with four lasers, 16 detection parameters, and the Attune™ NxT Autosampler, the NxT combines expanded multiparametric immunophenotyping together with high throughput data acquisition. The NxT system enables the identification […]

Molecular Imaging Embraces XSTRAHL Targeted Irradiation Technology

ANN ARBOR, MICHIGAN (October 28, 2015) — Molecular Imaging, Inc., a leading provider of preclinical oncology services, announced today that it has entered into a collaboration agreement with Xstrahl, Inc.  Under the agreement, Molecular Imaging will add Xstrahl’s industry-leading Small Animal Radiation Research Platform (SARRP) to its existing portfolio of technologies supporting its services business.  […]

James Norman joins Molecular Imaging, Inc. as Vice President of Sales

Molecular Imaging, Inc. is pleased to announce the appointment of James M. Norman as Vice President, Sales, effective May 12, 2014. For the last seven years, Mr. Norman has led the commercial establishment and growth of Maccine Pte Ltd. as their global head of business development. Maccine is a leader in providing high quality non-clinical […]

Maryland R. Franklin, Ph.D. joins Molecular Imaging, Inc. as the new Director of Oncology Pharmaco-Imaging

Ann Arbor, MI March 12, 2014 Molecular Imaging, Inc. (MII), a contract research organization providing preclinical pharmacology and multi-modality preclinical in vivo imaging services to pharmaceutical and biotechnology companies, today announced that Maryland R. Franklin, Ph.D. has joined the company as the new Director of Oncology Pharmaco-Imaging. Dr. Franklin was formerly at OSI Pharmaceuticals (a wholly owned […]

Future Pharmaceuticals

Future Image Download PDF: 300.12_200811-future_pharma._future_image.pdf

Drug Discovery & Development: Coming Into Focus

What if the experimental subject in a longitudinal study could serve as its own control? Behold: the novel advantages of in vivo toxicology imaging Download PDF: 300.3_200812-drug_discovery._coming_into_focus_0.pdf